Retirement Systems of Alabama Buys 12,138 Shares of Jazz Pharmaceuticals PLC $JAZZ

Retirement Systems of Alabama lifted its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 7.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 171,801 shares of the specialty pharmaceutical company’s stock after purchasing an additional 12,138 shares during the period. Retirement Systems of Alabama owned 0.26% of Jazz Pharmaceuticals worth $39,775,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of JAZZ. USA Financial Formulas bought a new position in Jazz Pharmaceuticals during the first quarter valued at $25,000. Pension & Wealth Management Advisors Inc. purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at $32,000. Ameritas Advisory Services LLC purchased a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $47,000. Westpac Banking Corp bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth $51,000. Finally, Elevation Wealth Partners LLC grew its stake in shares of Jazz Pharmaceuticals by 156.4% during the 3rd quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock worth $60,000 after acquiring an additional 158 shares during the period. Institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on JAZZ shares. Weiss Ratings cut Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, October 28th. Robert W. Baird increased their target price on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Truist Financial increased their target price on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Piper Sandler boosted their price target on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $293.00.

Jazz Pharmaceuticals Stock Up 0.8%

JAZZ stock opened at $245.43 on Wednesday. The stock has a 50-day simple moving average of $229.26 and a two-hundred day simple moving average of $218.48. Jazz Pharmaceuticals PLC has a twelve month low of $132.10 and a twelve month high of $266.38. The firm has a market capitalization of $15.75 billion, a PE ratio of 83.48, a PEG ratio of 0.44 and a beta of 0.38. The company has a quick ratio of 1.64, a current ratio of 1.82 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the prior year, the firm posted $8.13 earnings per share. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, EVP Robert Iannone sold 76,921 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the sale, the executive vice president owned 65,686 shares of the company’s stock, valued at approximately $16,401,794.20. This represents a 53.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renée Galá sold 1,000 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $225.37, for a total transaction of $225,370.00. Following the completion of the transaction, the chief executive officer directly owned 140,394 shares of the company’s stock, valued at approximately $31,640,595.78. The trade was a 0.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 171,342 shares of company stock worth $41,420,491 in the last ninety days. Insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.